Article: Current Management Options in Metastatic Renal Cell Cancer.
2017 Volume 11, Issue 2, Page(s) 339
Abstract: Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months ... ...
| Abstract | Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months with 1-year survival of only 29%. The management of metastatic renal cell cancers traditionally relied on systemic immunotherapy with attendant high morbidity but after the year 2005 the use of effective targeted therapy with tolerable side effect profile has improved the survival from 10.2 months in the cytokine era to 17.7 months. This article reviews the past, present and future options in the management of metastatic renal cancer. |
|---|---|
| Language | English |
| Publishing date | 2017-06-14 |
| Publishing country | Italy |
| Document type | Journal Article ; Review |
| ZDB-ID | 2390302-8 |
| ISSN | 1970-5565 ; 1970-5565 ; 1970-5557 |
| ISSN (online) | 1970-5565 |
| ISSN | 1970-5565 ; 1970-5557 |
| DOI | 10.4081/oncol.2017.339 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6550: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.